554 related articles for article (PubMed ID: 33158378)
1. Ceramides in Metabolism: Key Lipotoxic Players.
Chaurasia B; Summers SA
Annu Rev Physiol; 2021 Feb; 83():303-330. PubMed ID: 33158378
[TBL] [Abstract][Full Text] [Related]
2. Ceramides - Lipotoxic Inducers of Metabolic Disorders.
Chaurasia B; Summers SA
Trends Endocrinol Metab; 2015 Oct; 26(10):538-550. PubMed ID: 26412155
[TBL] [Abstract][Full Text] [Related]
3. The Lard Works in Mysterious Ways: Ceramides in Nutrition-Linked Chronic Disease.
Nicholson RJ; Norris MK; Poss AM; Holland WL; Summers SA
Annu Rev Nutr; 2022 Aug; 42():115-144. PubMed ID: 35584813
[TBL] [Abstract][Full Text] [Related]
4. Contribution of specific ceramides to obesity-associated metabolic diseases.
Hammerschmidt P; Brüning JC
Cell Mol Life Sci; 2022 Jul; 79(8):395. PubMed ID: 35789435
[TBL] [Abstract][Full Text] [Related]
5. Ceramides in insulin resistance and lipotoxicity.
Summers SA
Prog Lipid Res; 2006 Jan; 45(1):42-72. PubMed ID: 16445986
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Phytochemicals in Obesity-Related Metabolic Diseases: Focus on Ceramide Metabolism.
Kim E; Jeon S
Nutrients; 2023 Jan; 15(3):. PubMed ID: 36771408
[TBL] [Abstract][Full Text] [Related]
7. Targeting ceramide metabolism in obesity.
Aburasayn H; Al Batran R; Ussher JR
Am J Physiol Endocrinol Metab; 2016 Aug; 311(2):E423-35. PubMed ID: 27382035
[TBL] [Abstract][Full Text] [Related]
8. A ceramide-centric view of insulin resistance.
Chavez JA; Summers SA
Cell Metab; 2012 May; 15(5):585-94. PubMed ID: 22560211
[TBL] [Abstract][Full Text] [Related]
9. Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.
Meikle PJ; Summers SA
Nat Rev Endocrinol; 2017 Feb; 13(2):79-91. PubMed ID: 27767036
[TBL] [Abstract][Full Text] [Related]
10. Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms.
Chavez JA; Summers SA
Biochim Biophys Acta; 2010 Mar; 1801(3):252-65. PubMed ID: 19796706
[TBL] [Abstract][Full Text] [Related]
11. Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease.
Zhu C; Huai Q; Zhang X; Dai H; Li X; Wang H
Int J Biol Sci; 2023; 19(1):311-330. PubMed ID: 36594091
[TBL] [Abstract][Full Text] [Related]
12. The role of ceramides in metabolic disorders: when size and localization matters.
Turpin-Nolan SM; Brüning JC
Nat Rev Endocrinol; 2020 Apr; 16(4):224-233. PubMed ID: 32060415
[TBL] [Abstract][Full Text] [Related]
13. Sphingolipid Metabolism: New Insight into Ceramide-Induced Lipotoxicity in Muscle Cells.
Bandet CL; Tan-Chen S; Bourron O; Le Stunff H; Hajduch E
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678043
[TBL] [Abstract][Full Text] [Related]
14. Sphingolipids as a Culprit of Mitochondrial Dysfunction in Insulin Resistance and Type 2 Diabetes.
Roszczyc-Owsiejczuk K; Zabielski P
Front Endocrinol (Lausanne); 2021; 12():635175. PubMed ID: 33815291
[TBL] [Abstract][Full Text] [Related]
15. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.
Holland WL; Summers SA
Endocr Rev; 2008 Jun; 29(4):381-402. PubMed ID: 18451260
[TBL] [Abstract][Full Text] [Related]
16. Ceramides are necessary and sufficient for diet-induced impairment of thermogenic adipocytes.
Chaurasia B; Ying L; Talbot CL; Maschek JA; Cox J; Schuchman EH; Hirabayashi Y; Holland WL; Summers SA
Mol Metab; 2021 Mar; 45():101145. PubMed ID: 33352310
[TBL] [Abstract][Full Text] [Related]
17. Ceramides are fuel gauges on the drive to cardiometabolic disease.
Wilkerson JL; Tatum SM; Holland WL; Summers SA
Physiol Rev; 2024 Jul; 104(3):1061-1119. PubMed ID: 38300524
[TBL] [Abstract][Full Text] [Related]
18. Ceramides in Adipose Tissue.
Li Y; Talbot CL; Chaurasia B
Front Endocrinol (Lausanne); 2020; 11():407. PubMed ID: 32636806
[TBL] [Abstract][Full Text] [Related]
19. Ceramide Acyl Chain Length and Its Relevance to Intracellular Lipid Regulation.
Ho QWC; Zheng X; Ali Y
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077094
[TBL] [Abstract][Full Text] [Related]
20. Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes.
Bellini L; Campana M; Mahfouz R; Carlier A; Véret J; Magnan C; Hajduch E; Le Stunff H
Expert Opin Ther Targets; 2015; 19(8):1037-50. PubMed ID: 25814122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
